Publications

BibTex format

@article{Hardy:2002,
author = {Hardy, GA and Imami, N and Gotch, FM},
journal = {J HIV Ther},
pages = {40--45},
title = {Improving HIV-specific immune responses in HIV-infected patients.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/12553687},
volume = {7},
year = {2002}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Deficiencies in potentially highly protective HIV-1-specific immune responses have led to interventions with immunotherapeutic strategies such as post-exposure vaccination. The application of exogenous antigen to the HIV-infected individual by therapeutic vaccination might be expected to induce renewed virus-specific effector T-cell and neutralising-antibody responses. However, the nature of HIV-1 immunopathogenicity precludes this approach: high levels of viral turnover, persistent expression and presentation of HIV-1 antigen to the immune system, T-cell hyperactivation and exhaustion and clonal T-cell anergy all successfully counter any effect of exogenous antigen. Even with the use of highly active antiretroviral therapy (HAART), when HIV-1 activity is profoundly restricted, the induction of immune responses remains problematic. Different vaccine strategies are currently being tested, including a whole killed virus preparation (Remune), a yeast virus-like particle (p24 VLP), whole antigen preparations (VaxSyn), canarypox immunogens (ALVAC) and DNA plasmids. Therapeutic vaccine strategies currently in the earliest stages of development include adenovirus vectors and a topical DNA preparation, DermaVir.
AU  - Hardy,GA
AU  - Imami,N
AU  - Gotch,FM
EP  - 45
PY  - 2002///
SN  - 1462-0308
SP  - 40
TI  - Improving HIV-specific immune responses in HIV-infected patients.
T2  - J HIV Ther
UR  - https://www.ncbi.nlm.nih.gov/pubmed/12553687
VL  - 7
ER  -

Download

DrNesrinaImami

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)